Ulrike Nitz

13.4k total citations · 1 hit paper
135 papers, 2.4k citations indexed

About

Ulrike Nitz is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ulrike Nitz has authored 135 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Cancer Research, 90 papers in Oncology and 56 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ulrike Nitz's work include Breast Cancer Treatment Studies (87 papers), Advanced Breast Cancer Therapies (44 papers) and Cancer Treatment and Pharmacology (42 papers). Ulrike Nitz is often cited by papers focused on Breast Cancer Treatment Studies (87 papers), Advanced Breast Cancer Therapies (44 papers) and Cancer Treatment and Pharmacology (42 papers). Ulrike Nitz collaborates with scholars based in Germany, United States and Switzerland. Ulrike Nitz's co-authors include Nadia Harbeck, Oleg Gluz, C Liedtke, Lajos Pusztai, Nina Gottschalk, Ronald Kates, Matthias Christgen, Hans Kreipe, Christoph Thomssen and Christian Jackisch and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Ulrike Nitz

125 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Triple-negative breast cancer—current status and future directions

2009 513 citations Oleg Gluz, C Liedtke et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ulrike Nitz Germany	22	1.5k	1.1k	561	469	331	135	2.4k
Oleg Gluz Germany	23	1.5k 1.0×	1.1k 1.0×	625 1.1×	521 1.1×	301 0.9×	142	2.4k
G. N. Hortobágyi United States	23	1.7k 1.2×	962 0.9×	573 1.0×	543 1.2×	253 0.8×	106	2.7k
Per Malmström Sweden	26	1.3k 0.9×	1.1k 1.0×	1.0k 1.8×	515 1.1×	260 0.8×	61	2.6k
S. Shak United States	12	1.1k 0.7×	749 0.7×	609 1.1×	381 0.8×	302 0.9×	40	1.8k
Alvaro Moreno‐Aspitia United States	26	1.9k 1.3×	781 0.7×	632 1.1×	664 1.4×	481 1.5×	105	2.7k
Elin Borgen Norway	31	2.3k 1.5×	1.8k 1.6×	950 1.7×	756 1.6×	178 0.5×	88	3.3k
Anne‐Vibeke Lænkholm Denmark	30	1.2k 0.8×	1.2k 1.1×	1.2k 2.1×	461 1.0×	302 0.9×	120	2.6k
Federico Piacentini Italy	23	1.3k 0.9×	718 0.6×	386 0.7×	517 1.1×	328 1.0×	115	1.9k
Binghe Xu China	26	2.4k 1.6×	1000 0.9×	666 1.2×	1.0k 2.2×	482 1.5×	149	3.1k
Akihiko Shimomura Japan	22	1.1k 0.7×	537 0.5×	751 1.3×	536 1.1×	331 1.0×	132	2.0k

Countries citing papers authored by Ulrike Nitz

Since Specialization

Citations

This map shows the geographic impact of Ulrike Nitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrike Nitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrike Nitz more than expected).

Fields of papers citing papers by Ulrike Nitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrike Nitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrike Nitz. The network helps show where Ulrike Nitz may publish in the future.

Co-authorship network of co-authors of Ulrike Nitz

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrike Nitz. A scholar is included among the top collaborators of Ulrike Nitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrike Nitz. Ulrike Nitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Graeser, Monika, Oleg Gluz, Peter Schmid, et al.. (2024). Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial.. Journal of Clinical Oncology. 42(16_suppl). 590–590. 1 indexed citations

Harbeck, Nadia, Michael Braun, Oleg Gluz, et al.. (2024). Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.. Journal of Clinical Oncology. 42(16_suppl). TPS631–TPS631. 2 indexed citations

Gluz, Oleg, Monika Graeser, Ulrike Nitz, et al.. (2023). 120TiP Premenopausal women with breast cancer optimally treated with OFS (PROOFS). ESMO Open. 8(1). 101344–101344. 1 indexed citations

Schmidt, Marcus, Ulrike Nitz, Toralf Reimer, et al.. (2023). Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate – The ICE randomized clinical trial. European Journal of Cancer. 194. 113324–113324. 1 indexed citations

Mackelenbergh, Marion van, Fenja Seither, Volker Möbus, et al.. (2022). Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. European Journal of Cancer. 166. 185–201. 9 indexed citations

Gregorio, Amelie de, Wolfgang Janni, Thomas W. P. Friedl, et al.. (2022). The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. British Journal of Cancer. 126(12). 1715–1724. 23 indexed citations

Harbeck, Nadia, Ulrike Nitz, Matthias Christgen, et al.. (2020). LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results. Annals of Oncology. 31. S1146–S1146. 5 indexed citations

Kümmel, Sherko, Jens‐Uwe Blohmer, Andreé Faridi, et al.. (2018). Autologous Lipotransfer - Daily Therapeutic Practice in Breast Cancer: An Intergroup Analysis Encompassing NOGGO, WSG, GBG, AWO Gyn and DGPRÄC. Breast Care. 14(3). 165–169. 1 indexed citations

Gluz, Oleg, Ulrike Nitz, Matthias Christgen, et al.. (2017). Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results. Annals of Oncology. 28. v606–v606. 1 indexed citations

10.

Gluz, Oleg, C Liedtke, Jens Huober, et al.. (2016). Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Annals of Oncology. 27(6). 1035–1040. 10 indexed citations

11.

Müller, Philipp, Matthias Kreuzaler, Tarik A. Khan, et al.. (2015). Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Science Translational Medicine. 7(315). 315ra188–315ra188. 269 indexed citations

12.

Aapro, Matti, Volker Moebus, Ulrike Nitz, et al.. (2014). Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis. Annals of Oncology. 26(4). 688–695. 21 indexed citations

13.

Nitz, Ulrike, Oleg Gluz, I. Zuna, et al.. (2013). Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. Annals of Oncology. 25(1). 75–80. 15 indexed citations

14.

Rom, Joachim, Claudia Schumacher, Oleg Gluz, et al.. (2013). Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers. Breast Care. 8(3). 208–214. 12 indexed citations

15.

Moebus, Volker, Christian Jackisch, Hans-Joachim Lueck, et al.. (2010). Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study. Journal of Clinical Oncology. 28(17). 2874–2880. 126 indexed citations

16.

Harbeck, Nadia, Marwa Rashad Salem, Ulrike Nitz, Oleg Gluz, & Cornelia Liedtke. (2010). Personalized treatment of early-stage breast cancer: Present concepts and future directions. Cancer Treatment Reviews. 36(8). 584–594. 41 indexed citations

17.

Gluz, Oleg, Peter J. Wild, Evelyn Ting, et al.. (2008). Nuclear karyopherin α2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. International Journal of Cancer. 123(6). 1433–1438. 66 indexed citations

18.

Gluz, Oleg, Ulrike Nitz, Nadia Harbeck, et al.. (2008). Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Annals of Oncology. 19(5). 861–870. 84 indexed citations

19.

Ting, Evelyn, Oleg Gluz, Alexander Herr, et al.. (2007). Protein Expression Profiling in High-Risk Breast Cancer Patients Treated with High-Dose or Conventional Dose–Dense Chemotherapy. Clinical Cancer Research. 13(2). 488–497. 57 indexed citations

20.

Nitz, Ulrike & Peter Dall. (2002). Neue Therapieansätze: stammzellgestützte Hochdosischemotherapie und molekulare Strategien beim Mammakarzinom. Der Internist. 43(3). 364–372.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact